SIGLEC-1 Expression in a Cohort of Patients With Lupus Erythematosus Treated With Anifrolumab

JAMA Dermatology 2026 Open access

Read full text
Authors: Alice Horisberger, Katharina S. Shaw, Rochelle Castillo, Eilish Dillon, Kathryne E. Marks, Ifeoluwakiisi Adejoorin, Emily G. Oakes, Heather Roland, Julia Caldropoli, Karen H. Costenbader, Avery LaChance, Ruth Ann Vleugels
+1 more Deepak A. Rao
DOI: 10.1001/jamadermatol.2025.5920
Cited by: 1
References: 6

Abstract

This cohort study evaluates the usefulness of measuring SIGLEC-1 expression for tracking response to anifrolumab therapy in patients with lupus erythematosus.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Ubiquitin and proteasome pathways T-cell and B-cell Immunology

Publication details

Journal / source
JAMA Dermatology
Publisher
American Medical Association (AMA)
Volume
162
Issue
4
Pages
418–418
Publication date
11 February 2026
Language
EN